Overview

SB-659032 Platelet Aggregation Study

Status:
Completed

Trial end date:
2005-12-01

Target enrollment:

Participant gender:

Summary

This study is designed to assess whether inhibition of plasma Lp-PLA2 activity impacts platelet function as assessed by ex vivo platelet aggregation tests and in vivo plasma biomarkers.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline